Iowh
Background:
The Institute for One World Health (IOWH), the first non-profit pharmaceutical company in the U.S., was founded in 2000 by Dr. Victoria Hale. The aim of this organization is to develop safe, effective, and affordable new medicines for people with infectious diseases in the developing world and thus help in improving global health. IOWH decided to find cures for diseases for which no drugs were available and no or little R&D had been conducted.
IOWH picks up the compounds, which due to the lack of commercial viability remained unexploited by the pharmaceutical companies, develops them, conducts pre-clinical and clinical tests, and obtains regulatory approvals for the drugs. IOWH is organized and managed as a regular pharmaceutical company with Dr. Hale at the helm as CEO. It employs full time staff and supported by volunteered experts as scientific advisors.
Business Model:
IOWH has an interesting model to circumvent the high R&D costs involved in pharmaceutical industry. Its business model is based on positioning IOWH as a credible potential company in the pharmaceutical industry to stimulate the inflow of funds from the prospective ‘donors’ and also to encourage other pharmaceutical and biotechnological companies to donate or share their valuable rights on their patent compounds which are not yet exploited fully. The functioning of the business model employs assembling an experienced and dedicated team of pharmaceutical scientists, identifying the promising compounds that could be developed into effective and affordable medicines and partnering with companies, hospitals and other organizations that share the same vision as that of IOWH and would help to advance IOWH towards its mission. IOWH also intends to partner with local manufacturing and distribution companies to ensure affordability and availability of the medicines to the patients in need. We identified the following key issues which are probably essential to sustain the business
The Institute for One World Health (IOWH), the first non-profit pharmaceutical company in the U.S., was founded in 2000 by Dr. Victoria Hale. The aim of this organization is to develop safe, effective, and affordable new medicines for people with infectious diseases in the developing world and thus help in improving global health. IOWH decided to find cures for diseases for which no drugs were available and no or little R&D had been conducted.
IOWH picks up the compounds, which due to the lack of commercial viability remained unexploited by the pharmaceutical companies, develops them, conducts pre-clinical and clinical tests, and obtains regulatory approvals for the drugs. IOWH is organized and managed as a regular pharmaceutical company with Dr. Hale at the helm as CEO. It employs full time staff and supported by volunteered experts as scientific advisors.
Business Model:
IOWH has an interesting model to circumvent the high R&D costs involved in pharmaceutical industry. Its business model is based on positioning IOWH as a credible potential company in the pharmaceutical industry to stimulate the inflow of funds from the prospective ‘donors’ and also to encourage other pharmaceutical and biotechnological companies to donate or share their valuable rights on their patent compounds which are not yet exploited fully. The functioning of the business model employs assembling an experienced and dedicated team of pharmaceutical scientists, identifying the promising compounds that could be developed into effective and affordable medicines and partnering with companies, hospitals and other organizations that share the same vision as that of IOWH and would help to advance IOWH towards its mission. IOWH also intends to partner with local manufacturing and distribution companies to ensure affordability and availability of the medicines to the patients in need. We identified the following key issues which are probably essential to sustain the business